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ABSTRACT
Mechanisms that preserve genome integrity are
highly important during the normal life cycle of
human cells. Loss of genome protective mechan-
isms can lead to the development of diseases
such as cancer. Checkpoint kinases function in the
cellular surveillance pathways that help cells to
cope with DNA damage. Importantly, the checkpoint
kinases ATR, CHK1 and WEE1 are not only activated
in response to exogenous DNA damaging agents,
but are active during normal S phase progression.
Here, we review recent evidence that these check-
point kinases are critical to avoid deleterious DNA
breakage during DNA replication in normal, unper-
turbed cell cycle. Possible mechanisms how loss of
these checkpoint kinases may cause DNA damage
in S phase are discussed. We propose that the
majority of DNA damage is induced as a conse-
quence of deregulated CDK activity that forces un-
scheduled initiation of DNA replication. This could
generate structures that are cleaved by DNA endo-
nucleases leading to the formation of DNA double-
strand breaks. Finally, we discuss how these S
phase effects may impact on our understanding of
cancer development following disruption of these
checkpoint kinases, as well as on the potential of
these kinases as targets for cancer treatment.
INTRODUCTION
Maintenance of genome integrity is essential to prevent
development of diseases associated with genomic instabil-
ity such as cancer and neurodegenerative disorders (1).
The genome integrity of human cells is frequently threat-
ened by DNA damage caused by exogenous or endogen-
ous sources. To counteract such threat, human cells
contain a network of DNA damage surveillance
pathways that maintain genome integrity. These surveil-
lance pathways control processes such as DNA repair,
cell-cycle checkpoints, apoptosis and transcription. The
checkpoint kinases ATR, CHK1 and WEE1 are key regu-
lators of DNA damage surveillance pathways. ATR and
CHK1 regulate the S and G2 checkpoints (2–5), replica-
tion initiation and replication fork stability (6–10) and
homologous recombination repair (11–13). CHK1 also
controls mitotic entry in unperturbed cells (14) and was
reported to play a role in mitotic spindle checkpoint
function (15), and in control of transcription (16).
WEE1 has a major cell-cycle function in control of the
G2/M transition (17,18).
ATR, CHK1 and WEE1 are in fact active during un-
perturbed normal cell-cycle progression, and all three
kinases have roles besides their functions in the response
to exogenous DNA damage. Deletion of ATR, CHK1 or
WEE1 in mice causes embryonic lethality (19–23),
demonstrating that these checkpoint kinases are essential
for embryonic development. Importantly, recent work
has revealed that the activities of these kinases are
required during normal S phase to avoid deleterious
DNA breakage, and thereby prevent loss of genome integ-
rity in the absence of exogenous DNA damaging agents
(24–27). Here, we review the progress in this area with
focus on discussing the potential mechanisms involved
in causing DNA breakage following inhibition of these
checkpoint kinases. We also discuss the possible
impact of these ﬁndings on our understanding of the
roles of these checkpoint kinases in cancer development,
and on the potential of these kinases as targets for cancer
treatment.
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Before discussing the mechanisms how ATR, CHK1 and
WEE1 are required to prevent loss of integrity in normal S
phase, we brieﬂy summarize the current knowledge about
how these kinases are activated and how they are thought
to control DNA replication.
Activation of ATR occurs upon the generation of
lesions containing single-stranded DNA (ssDNA) (28),
which evolve at stalled replication forks and following
processing of DNA strand breaks (29,30). Coating of
ssDNA by the single-strand binding protein RPA helps
loading of ATR to DNA damage sites (31–33). ATR rec-
ognition of RPA-coated ssDNA is dependent on the
ATR-interacting protein (ATRIP) (34), which binds
RPA directly (35). ATR activation is also dependent on
TOPBP1, RAD17 and the 9-1-1 (RAD9-RAD1-HUS1)
complex (36–38). RAD17 is recruited by RPA-coated
ssDNA and loads the 9-1-1 complex, which subsequently
recruits TOPBP1 and brings it in close proximity to ATR
so that TOPBP1 can activate ATR via direct interaction
(39). Studies in Xenopus extracts suggest that ssDNA in
itself is not sufﬁcient to cause strong activation of ATR.
While ATR activation by naked ssDNA pieces was low,
high levels of ATR activation were observed at areas of
ssDNA with 50-primed ends (37). It has been suggested
that these ends may be the loading site for the 9-1-1
complex (40). Thus, small pieces of ssDNA generated
during normal replication do not lead to strong check-
point activation, although they might potentially contrib-
ute to the low levels of ATR activation observed during
normal unperturbed cell cycle.
CHK1 is a direct downstream target of ATR. ATR
phosphorylates CHK1 on Ser 317 and Ser345 and stimu-
lates its function (22,41,42). After the ATR induced phos-
phorylation, CHK1 undergoes autophosphorylation at
Ser296 (43,44). The DNA damage-induced ATR phos-
phorylation most likely does not up-regulate CHK1
kinase activity per se. However, phosphorylated CHK1
can dissociate from chromatin (45,46), and ATR regula-
tion of CHK1 may thereby control transition of DNA
damage signals from chromatin to its targets.
The activity of WEE1 increases during S and G2 phases
in parallel with its increased protein level (47), and can be
stimulated by the CDK-interacting protein CABLES (48).
In budding yeast, WEE1 activity is also stimulated by low
levels of CDK activity in G2 phase (49). In Xenopus,
activated XCHK1 phosphorylates the XWee1 kinase,
contributing to increased Tyrosine 15 phosphorylation
and inhibition of CDK activity following CHK1 activa-
tion (50). This regulatory mechanism has so far not been
described in mammalian cells. At entry into mitosis WEE1
is inhibited both by phosphorylation and degradation
allowing rapid increase in CDK activity (49,51–53).
Subsequent CDK phosphorylation primes WEE1 for
ubiquitylation via the b-TRCP SCF type of ubiquitin
ligase, and this activity may be further supported by the
Tome-1 SCF ubiquitin ligase (54).
The cell-cycle regulatory roles of ATR/CHK1 and
WEE1 in S and G2 phases are mainly through regulation
of CDK activity (Figure 1). WEE1 directly catalyses the
inhibitory Tyrosine 15 phosphorylation of CDK1 and
CDK2 and thereby inhibits CDK activity (18,47).
Following its activation, CHK1 directly phosphorylates
CDC25A (3), facilitated by 14-3-3g (44). CHK1 activates
NEK11 that also phosphorylates CDC25A directly (55),
and the concerted action of the two kinases promotes the
ubiquitin dependent degradation of CDC25A. The deg-
radation of CDC25A leads to decreased removal of the
phosphorylation of the CDK Tyrosine 15 residue. This
results in inhibition of CDK activity that induces cell-cycle
arrest (33,56). CHK1 can also phosphorylate CDC25B
and CDC25C (5,57), which may also contribute to
restrain CDK activity.
CDK mediated control of DNA replication initiation
When cells reach S phase, DNA replication is initiated
from a large number of chromosomal locations known
as replication origins. The precise activation of origins is
a key part of replication control, because cells are thought
to be unable to regulate the speed of the DNA polymer-
ases. The initiation of DNA replication is triggered by the
action of the CDK kinases and DBF4-CDC7 kinase
(DDK) (58,59). CDK2 is considered a key CDK in
control of DNA replication in S phase, although CDK1
can compensate if CDK2 is disabled (60). Once activated,
CDK2 activity promotes origin ﬁring through loading of
CDC45L and AND-1/CTF4 at origins (61,62). The
presence of CDC45L and AND-1/CTF4 at origins are
required for origin unwinding by the MCM helicase,
and thereby also required for the subsequent binding of
the primase DNA polymerase (Pol) alpha that initiates
DNA synthesis (61,63). Recent data suggest that the
novel replication factors Treslin and GEMC1 are key
Figure 1. Regulation of CDK activity by ATR, CHK1 and WEE1
determines replication initiation during normal S phase. CDK activity
is negatively regulated by phosphorylation of the Tyrosine 15 residue.
This residue is phosphorylated by WEE1 and dephosphorylated by
CDC25. CDC25 is negatively regulated by CHK1, which in turn is
stimulated by the ATR kinase.
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loading (64,65).
In addition to promoting origin ﬁring, CDK activity
also seems to regulate the activation of individual replica-
tion clusters and the overall timing of replication through
S phase, although this regulation is not well understood
(66–69). A substantial number of origins are ﬁred at dis-
tinct times through S phase to allow coordinated execu-
tion of DNA replication. In fact, more origins are licensed
than are ever used, and in a normal S phase most origins
are replicated passively by replication forks coming from
neighbouring activated origins (70). When replication fork
stalling or replication stress occurs, local dormant origins
will ﬁre to compensate for the lack of replication. Under
conditions of exogenous DNA damage, checkpoint
pathways block the activation of origins that normally
ﬁre throughout S phase, which constitutes the basis for
the S phase checkpoint (70–72).
ATR, CHK1 and WEE1 control CDK activity to support
genome integrity during DNA replication
Recent studies have uncovered that ATR, CHK1 and
WEE1 are critical for coordinated duplication of the
genome and preventing a catastrophic outcome of the sen-
sitive replication process. In response to CHK1 inhibition
by the drugs UCN-01 or CEP-3891, or siRNA mediated
depletion of CHK1, the genome is rapidly destabilized and
accumulates a massive amount of DNA double-strand
breaks (27). This damage is preceded by massive accumu-
lation of ssDNA near the replication fork. All these
critical downstream effects of CHK1 inhibition are de-
pendent on CDK activity (27). The deleterious effects of
CHK1 inhibition can be blocked by depleting CDC25A,
the CDK activator controlled by CHK1. Furthermore,
cellular ﬁtness of CHK1 depleted cells is markedly
improved by co-depleting CDC25A (26). Consistent with
these results, conditional CHK1 heterozygosity causes ac-
cumulation of DNA damage during DNA replication in
mice in the absence of exogenous DNA damaging agents
(24). WEE1 depletion by siRNA transfection also rapidly
induces DNA damage in S phase in replicating areas,
which is accompanied by a marked accumulation of
ssDNA. Similar to the effects of CHK1 inhibition, these
deleterious S phase effects of WEE1 depletion are highly
dependent on CDK activity (26).
Reduced ATR function can also cause a DNA damage
response in S phase cells. Cultured MEFs and embryos
from ATR mutated Seckel syndrome mice revealed high
incidence of Cyclin A positive cells with strong
pan-nuclear staining of g-H2AX, consistent with increased
replication stress (25). Induction of DNA damage, as
assessed by increased g-H2AX staining, was also
observed in another mouse model hypomorphic for
ATR (73). ATR depletion leads to deregulation of
CDC25A levels in the absence of exogenous replication
inhibitors and DNA damaging agents (74). In line with
this, the DNA damage occurring after ATR inhibition is
also blocked by depleting CDC25A, indicating that the
loss of genomic integrity occurs as a consequence of de-
regulation of the ATR-CHK1-CDC25A-CDK pathway
(75). These results suggest that similar to CHK1 and
WEE1, ATR is also required to prevent formation of dele-
terious DNA lesions during normal S phase through
control of CDK activity.
Increased CDK activity leads to unscheduled initiation of
DNA replication origins
When ATR and CHK1 activity is lost, several cellular
pathways are affected and could potentially contribute
to the devastating cellular outcome. However, the loss of
each of WEE1, ATR and CHK1 leads to increased CDK
activity (3,26,74–76) resulting in a loss of control of the
replication coordination. Inhibition of CHK1 leads to an
increased loading of replication factor CDC45L onto
chromatin, which is followed by a dramatic increase in
replication initiation. Shortly after, there is increased
ssDNA formation and RPA loading indicative of replica-
tion stress (27). In addition, CHK1 inhibition also causes
slower replication fork speed (6,7), however, this is likely
not directly due to the elevated CDK activity operating
at existing forks. In fact, it was suggested that CHK1 in-
directly promotes replication fork progression as a down-
stream consequence of the key role in control of
replication initiation (7). Similarly to CHK1, WEE1 de-
pletion causes increased ssDNA and RPA loading indica-
tive of replication stress (26). Drug-based WEE1
inhibition also leads to a very rapid increase in origin ﬁring
and slower replication fork speeds (our unpublished ob-
servations). Importantly, DNA damage arising after both
CHK1 and WEE1 inhibition, respectively, is ablated by
partial suppression of DNA replication initiation obtained
by depletion of CDC45L, CDT1 and MCM complex
members (26,27). Based on our previous data and the
common regulation of CDK activity by ATR/CHK1
and WEE1 kinases, we propose that the major cellular
defect leading to DNA breakage in S phase following de-
pletion of these kinases is CDK-driven unscheduled initi-
ation of a large number of origins (Figure 2). Supporting
the notion that CDK-driven events can lead to DNA
breakage in S phase, other ways of enhancing CDK
activity such as overexpression of Cyclin E, CDC25A or
E2F1 also causes DNA damage in S phase (77).
Interestingly, this chain of events has not been observed in
yeast. Elevated CDK activity can induce chromosomal
rearrangements in budding yeast by mechanisms rather in-
volving inhibition of DNA replication licensing. However,
these effects occurred only in G1 phase cells (78), and are
therefore different from the S phase effects observed in
human cells.
Unscheduled initiation is required for the generation of
DNA lesions at the replication fork
Although unscheduled initiation is involved in the massive
induction of DNA breaks after checkpoint kinase inhib-
ition, it is not clear how it speciﬁcally contributes to break
formation. A low but signiﬁcant number of DNA breaks
may be induced in several ways by the replication process
itself (79). Importantly, unwound, single-stranded DNA
at replication forks may be more susceptible to DNA
breakage. This could for example occur after free radical
Nucleic AcidsResearch, 2012, Vol.40,No. 2 479attacks on the DNA backbone; however, checkpoint kin-
ase inhibition is not expected to rapidly induce high levels
of free radicals. In addition, ssDNA breaks existing in
front of the replication fork in the template DNA can
be converted to a double-strand break. During replication,
the template strands on each arm of replication forks
will no longer be base-paired to their original complemen-
tary template strands due to the actions of DNA helicases.
Consequently, single-strand lesions within template DNA
can cause double-strand breaks when the replication fork
reaches such lesions. Thus increased initiation of DNA
replication may in itself be sufﬁcient to cause small
amounts of DNA breakage if single-strand lesions are pre-
sent. However, additional events are most likely required
to achieve the massive induction of DNA breakage
observed following CHK1 or WEE1 inhibition (26,27).
In response to CHK1 inhibition, replication initiation
is ﬁrst increased, followed by subsequent fork stalling
(6,7,27). ATR and CHK1 are known to directly support
fork stability (79,80). It is therefore possible that lack of
ATR/CHK1-mediated support of stalled forks will lead to
fork collapse and DNA breaks. Data from budding yeast
have clearly documented an important role for ATR
(Mec1) and CHK1 (Rad53) in fork stability, however,
this function is observed under conditions of massive fork
stalling with hydroxyurea, an inhibitor of nucleotide me-
tabolism (81,82). It is not clear if fork destabilization is an
important contributor to the loss of genomic integrity after
checkpoint kinase inhibition under unperturbed conditions
in mammalian cells. Furthermore, it is important to note
that the genome integrity protection mediated by CHK1
operates largely through control of the CDC25A-CDK
pathway. Similarly, WEE1 also controls genome integrity
via suppression of CDK activity (26). Given these obser-
vations, it is apparent that elevated CDK activity should
destabilize existing replication forks if this was the major
mechanism. It remains to be shown if this is the case. In
addition, the massive unscheduled initiation could perhaps
result in unbalanced or insufﬁcient nucleotide pools that
could potentially lead to fork stalling and eventual
collapse, similar to that observed in cells treated with in-
hibitors of nucleotide metabolism such as hydroxyurea
(83). However, this would likely not occur with the
rapid kinetics observed after CHK1 and WEE1 inhibition,
where inhibitors induce DNA damage within 2h of treat-
ment. In contrast, DNA damage upon hydroxyurea treat-
ment alone is normally only observed after  24h of
treatment (84).
Checkpoint kinases or CDK may directly regulate
nucleases
In addition to the unscheduled initiation of origins, add-
itional possible explanations may more directly explain
the occurrence of double-strand breaks after checkpoint
kinase inhibition. It appears unlikely that such massive
DSB accumulation can arise without the activity of en-
zymes that break the DNA backbone, which is a very
solid structure. Stalled replication forks with exposed
ssDNA are processed by a number of enzymes to promote
genomic integrity. Homologous recombination pathways
can salvage stalled forks (85), and the remodelling of the
replication fork can generate structures that are resolved
by endonucleases such as MUS81/EME1. The resulting
double-strand break can be used to initiate fork restart
(86). However, the DSBs may have additional roles since
it can amplify checkpoint signalling to avoid premature
mitotic entry, and if present in large amount they may
serve to trigger cell death or senescence.
Nuclease substrate structures such as Holliday junctions
could potentially be formed due to elevated activity of
helicases that act upon stalled replication forks.
Following ATR/CHK1 and WEE1 inhibition, increased
CDK activity initiates excess origin ﬁring, and this may
lead to fork stalling due to shortage of important factors
such as nucleotides or key replication proteins (Figure 3).
The formation of nuclease substrates may also be pro-
moted by high level of torsional stress, potentially
occurring due to the elevated replicative helicase activities
at origins. Torsional stress in front of the fork is thought
to be able to promote reversal of the fork, since stress
relief can occur via fork reversal (Figure 3). Massive
fork reversal could potentially promote nuclease cleavage
of the Holliday junctions and thereby cause high number
of DNA double-strand breaks. Given that checkpoint in-
hibition leads to a large number of DNA replication fork
lesions, it is likely that excellent substrates for such nucle-
ases will appear in large quantity. The number of breaks
following nuclease activity may overwhelm the cellular
capacity to repair and process these lesions. The
presence of breaks is further problematic to cells as
CHK1 inhibition suppresses the HR pathway that would
normally process the breaks (11).
Figure 2. Model describing potential mechanisms how loss of check-
point kinases may cause DNA breakage during normal S phase. Loss
of WEE1, ATR or CHK1 leads to increased CDK activity, which
causes unscheduled replication initiation and subsequent DNA
breakage. Following massive unscheduled initiation of replication,
aberrant fork structures accumulate that are prone to breakage result-
ing in DNA DSBs. The high CDK activity may activate nucleases that
directly catalyse the formation of DNA DSBs.
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effects of the endonuclease MUS81/EME1 at stalled forks
(87). If CHK1 negatively regulates such endonucleases
during normal DNA replication, loss of CHK1 could
cause activation of the endonucleases and thereby lead
to massive induction of DNA breaks. On the other
hand, given that WEE1 depletion leads to a similar pheno-
type, it would rather be expected that increased CDK
activity is the causative effect in activating such a DNA
processing activity. Hence, it is possible that CDK has
direct targets with enzymatic activity, i.e. a nuclease ex-
hibiting aberrant activity, which could cause the massive
induction of DNA damage (Figure 2). It remains to be
determined to what extent such activities control genome
integrity as well as the nature of the deregulated enzymes.
Such nucleases should operate on the DNA structures
generated by the excess CDK activity, and the elucidation
of the contributions of such factors to genome integrity is
an important task for future research.
DNA damage arising in S phase after acute inhibition
of WEE1, ATR and CHK1 is likely dependent on nuclease
activities. However, more subtle degrees of inhibition of
these checkpoint kinases, as may more commonly occur
in vivo, does not necessarily depend on nucleases. Fragile
sites are areas in the genome that are prone to breakage
after ATR and CHK1 inhibition, and recent evidence
suggest that fragile sites can break in mitosis when sister
chromatids are separating in anaphase (88). These sites are
areas with few origins of replication, that critically depend
on functional origins of DNA replication since neighbour-
ing origins cannot compensate if forks stall and collapse
(89). The dysfunctional replication upon reduced WEE1,
ATR and CHK1 activity could lead to cells progressing
into mitosis with unreplicated DNA. This is likely en-
hanced by G2 checkpoint deﬁciency upon reduced activity
of these kinases. The outcome would be sister chromatid
connections when chromosomes separate in anaphase,
where breaks can occur by mechanical forces although
nucleases may also cleave these structures.
ATR, CHK1 and WEE1 can affect malignant
transformation
An important issue is whether loss of genomic integrity
arising from deregulated replication caused by ATR,
CHK1 and WEE1 disruption may contribute to cancer de-
velopment. Heterozygous ATR andCHK1 mutations have
been found in a subset of endometrial, colon, melanoma
and stomach cancers (90–96). Several reports suggest that
WEE1 function may also be compromised in cancer.
Recently, it was shown that microRNA-155 (miR-155),
which is frequently elevated in human cancers, cause
down-regulation of WEE1 (97). Moreover, prostate epi-
thelium, which is prone to prostate cancer development,
expressed very low levels of WEE1 (98).
Studies of ATR and CHK1 heterozogosity in mice also
suggest that compromised expression of these checkpoint
kinases might contribute to cancer development. One
report describes a modest increase in late tumour develop-
ment in ATR heterozygous (+/ ) mice (19), although
increased tumourigenesis was not observed in other
reports (25,99). However, on a mismatch repair-deﬁcient
(Mlh1  / ) background, ATR heterozygozity caused a
signiﬁcant increase in tumourigenesis (100). CHK1 hetero-
zygous (+/ ) mice were prone to tumourigenesis on a
WNT-1 transgenic background (22) and CHK1 heterozy-
gosity induced in mouse mammary glands using a Cre/
loxP system caused induction of mammary tumours in a
p53 heterozygous background (101). It seems plausible
that replication associated DNA damage due to insufﬁ-
cient CHK1 or ATR levels in S phase caused by hypo-
morphic mutations in these mice could contribute to
promote genomic instability and tumour progression.
On the other hand, WEE1 and CHK1 have also been
reported to be overexpressed in human cancers. WEE1 is
overexpressed in human glioblastoma and a subset of
breast cancers (102,103), and CHK1 mRNA expression
was elevated in MYC-ampliﬁed neuroblastoma (104).
Based on their role in restraining CDK activity, high
levels of WEE1 and CHK1 would be expected to suppress
rather than to promote cell growth. It may therefore seem
like a paradox that high levels of CHK1 or WEE1 are
found in human tumours where we rather would expect
a selective pressure towards genetic alterations allowing
uncontrolled growth. An explanation may be that these
tumours contain other genetic alterations that promote
increased CDK activity and replication stress, and if the
CDK activity was too high, the replication associated
damage would reach a level of severity resulting in cell
Figure 3. Model depicting how inhibition of checkpoint kinases may
lead to double-strand breaks after replication fork reversal. When
checkpoint kinases are inhibited CDK activity is up-regulated leading
to increased origin ﬁring. As a consequence of the enhanced origin
activity, replication factors such as polymerase subunits may become
limiting leading to fork stalling. Helicases can process stalled forks
leading to fork reversal, which generates substrates for DNA endo-
nucleases such as MUS81. Fork reversal may also occur due to
increased initiation of replication that generates enhanced torsional
stress due to helicase unwinding of the double-stranded DNA. This
stress can be relieved by fork reversal, thereby forming substrates for
endonuclease cleavage.
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of WEE1 or CHK1 to maintain CDK activity at sufﬁ-
ciently low levels for cell survival. Consistent with this
hypothesis, inhibition of WEE1 leads to induction of
DNA damage and cell death in tumours expressing high
WEE1 levels (102). Furthermore, MYC is known to cause
replication stress and elevated CHK1 expression was
found selectively in MYC-ampliﬁed neuroblastoma
(104). It is very possible that these cells depend on
CHK1 to tolerate the high level of MYC expression.
Can the replicative roles of the checkpoint kinases be
exploited for cancer treatment?
Checkpoint kinases guard against cancer-associated repli-
cation stress. In human tumours, replication stress
induced by oncogenes or hypoxia leads to increased acti-
vation of ATR/CHK1 in S phase cells (105–107).
Inhibitors of checkpoint kinases may therefore lead to se-
lective killing of cancer cells with elevated replication
stress (Figure 4). Currently, several inhibitors of CHK1
and WEE1 are in clinical trials (108–110); however this
is largely based on their G2 checkpoint abrogation
function and consequent induction of mitotic catastrophe.
When used in combination with chemotherapeutic agents
or radiation, inhibition of CHK1 or WEE1 can cause se-
lective sensitization of p53 negative cells (111–116). It has
been proposed that p53-negative cancer cells are particu-
larly sensitive to G2 checkpoint abrogation because they
lack the p53-dependent G1 checkpoint and therefore will
depend more on the G2 checkpoint for DNA damage
repair (117). On the other hand, p53-status does not
always predict responses to CHK1 inhibition (118–121).
Hence, additional effects of CHK1 inhibition, such as high
levels of replication stress due to unscheduled initiation,
likely contribute to cause cell death (11,27,104,122,123).
Following inhibition of WEE1 or CHK1, DNA breakage
in S phase (24,26,27) likely will cause killing of cancerous
as well as normal tissue cells. Upon inhibition of these
checkpoint kinases, loss of their function in restraining
CDK activity might therefore contribute to cause
unwanted normal tissue damage. However, the tumours
would often contain a higher fraction of cycling cells than
the surrounding normal tissue, as well as elevated replica-
tion stress due to genetic alterations (105,106) or hypoxia
(107). The deleterious S phase effects in response to inhib-
ition of these checkpoint kinases may therefore likely be
more severe in the tumour compared to normal tissues,
resulting in tumour selectivity. Moreover, treatments with
checkpoint kinase inhibitors would beneﬁt from a genetic
proﬁling of the cancer, as this could allow pre-selection of
patients with cancers that harbour marked replication
stress.
In agreement with such tumour selective effects in S
phase following checkpoint kinase inhibition, non-
transformed mammary epithelial cells showed less
g-H2AX staining, less replication issues and less apoptosis
compared to breast cancer cell lines in response to WEE1
inhibition (124). Inhibition of ATR can also sensitize
cancer cells and ATR has also been suggested as a thera-
peutic target based on its role in restraining replication,
although small-molecule ATR-inhibitors have only
recently started to become available (75,125). The possi-
bility of gaining tumour selective treatment based on in-
hibiting checkpoint kinases to induce deleterious DNA
damage selectively in S phase tumour cells is an exciting
task for future studies.
Figure 4. S phase effects during cancer treatment with inhibitors of ATR, CHK1 or WEE1 kinases may promote cancer speciﬁc killing. Cancer cells
often contain elevated CDK activity due to genetic alterations, which may induce replication failures leading to DNA damage in S phase and
subsequent genomic instability and tumour progression. Treatment with inhibitors of ATR, CHK1 or WEE1 further increases CDK activity leading
to massive CDK-mediated DNA damage in S phase and subsequent cell death of S phase cancer cells.
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The DNA replication process is highly regulated with a
large number of control mechanisms securing correct
timing and quality of the process. Recent work has
revealed that the checkpoint kinases ATR, CHK1 and
WEE1 are active during normal S phase progression in
the absence of exogenous DNA damage. Their activities
are critical to maintain genome integrity, and they largely
control genome integrity by restraining CDK activity.
Deregulated CDK activity will cause unscheduled ﬁring
of replication origins in S phase and thereby lead to the
induction of DNA breaks in a not yet fully understood
mechanism. Such replication-associated DNA lesions may
contribute to promote loss of genome integrity and cancer
progression following heterozygous mutations or other
ways of inactivation of ATR, CHK1 or WEE1 during
tumorigenesis. Furthermore, replication-associated DNA
damage occurring in response to small-molecule inhibitors
of ATR, CHK1 and WEE1 may be exploited to identify
new potential strategies for tumour selective treatment.
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